|
|
|
|
|
|
|
|
|
|
|
This page provides information concerning the Pharmacogenomics study topic.
|
|
|
|
A list of reports and correspondence related to this topic are provided below. This page also provides a summary of the sessions concerning this topic that have been held at SACGHS meetings so you can review the transcripts, presentation materials, and webcasts for the sessions that dealt with the topic.
|
|
|
|
Reports and Correspondence |
|
|
|
|
Realizing the Potential of Pharmacogenomics: Opportunities and Challenges
|
|
|
|
|
Public Comments on Draft Report
|
|
|
|
|
SACGHS letter to the Secretary of Health and Human Services (August 18, 2008)
|
|
Top of Page |
|
|
SACGHS Meetings |
|
|
|
|
November 19, 2007 - Session on Pharmacogenomics |
|
|
|
Overview of Final Draft SACGHS Report on Pharmacogenomics |
|
|
|
Kevin T. FitzGerald, S.J., Ph.D., Ph.D.
SACGHS Pharmacogenomics Task Force Chair
|
|
|
|
Slides
Webcast
|
|
|
|
|
Discussion and Consensus on Final Draft Report |
|
|
|
Facilitators: Dr. Tuckson and Dr. FitzGerald
|
|
|
|
Webcast before Lunch
Webcast after Lunch
|
|
|
|
|
|
|
July 10, 2007 - Update on the Development of the SACGHS Pharmacogenomics Report |
|
|
|
Kevin T. FitzGerald, S.J., Ph.D., Ph.D.
SACGHS Pharmacogenomics Task Force Chair
|
|
|
|
Slides
Webcast
|
|
|
|
|
November 13, 2006 - Pharmacogenomics Session |
|
|
|
Update on Efforts of the SACGHS Pharmacogenomics Task Force and Review of Draft Report |
|
|
|
Kevin T. FitzGerald, S.J., Ph.D., Ph.D.
Chair
SACGHS Task Force on Pharmacogenomics
|
|
|
|
Slides -
Webcast -
Transcript
|
|
|
|
|
June 26, 2006 - Pharmacogenomics Session |
|
|
|
|
Overview of Pharmacogenomics Session and Update on Efforts of the SACGHS Pharmacogenomics Task Force |
|
|
|
Emily Winn-Deen, Ph.D.
Chair
SACGHS Task Force on Pharmacogenomics |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Critical Path Initiative and FDA's Vision for Personalized Medicine |
|
|
|
Janet Woodcock, M.D.
Deputy Commissioner for Operations
FDA |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Q &A |
|
|
|
Facilitator: Dr. Winn-Deen |
|
|
|
Webcast
|
|
|
|
|
Full Committee Discussion |
|
|
|
Facilitator: Dr. Winn-Deen |
|
|
|
Webcast Part 1
Webcast Part 2
Transcript
|
|
|
|
|
Public Comments |
|
|
|
Webcast
Transcript
|
|
|
|
|
March 27, 2006 - Pharmacogenomics Session |
|
|
|
|
Update from the Pharmacogenomics Task Force |
|
|
|
Emily Winn-Deen, Ph.D.
Chair, SACGHS Task Force on Pharmacogenomics |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
FDA Draft Guidance for Industry and FDA Staff on Pharmacogenetic Tests and Genetic Tests for Heritable Markers |
|
|
|
Steve Gutman, M.D., MBA
Director, Office of In Vitro Diagnostic Device Evaluation and Safety, FDA |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Full Committee Discussion |
|
|
|
Webcast
Transcript
|
|
|
|
|
Public Comments |
|
|
|
Transcript
|
|
|
|
|
October 20, 2005 - Pharmacogenomics Session |
|
|
|
|
Update from the SACGHS Task Force on Pharmacogenomics |
|
|
|
Emily S. Winn-Deen, Ph.D.
SACGHS Task Force Chair |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Update from FDA |
|
|
|
Steven I. Gutman, M.D., M.B.A.
Director, Office of In Vitro Diagnostics
U.S. Food and Drug Administration |
|
|
|
Webcast
Transcript
|
|
|
|
|
Allen Rudman, Ph.D.
Associate Director, Office of Clinical Pharmacology and
Biopharmaceutics
Center for Drug Evaluation and Research, FDA |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Q&A and Committee Discussion |
|
|
|
Facilitator: Dr. Winn-Deen |
|
|
|
Webcast
Transcript
|
|
|
|
|
Public Comments |
|
|
|
Webcast
Transcript
|
|
|
|
|
Feasibility of Integrating Pharmacogenomics into Drug Development from an Economic Perspective |
|
|
|
Thomas A. Metcalfe
Head of Biomarker Program
F. Hoffmann-La Roche Ltd |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Economic Challenges of Integrating Pharmacogenomics into Clinical Practice |
|
|
|
Kathryn Phillips, Ph.D.
Professor of Health Economics and Health Services Research
Director, Program in Pharmacogenomics and Population Screening
University of California, San Francisco |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Q&A and Committee Discussion |
|
|
|
Facilitator: Dr. Winn-Deen |
|
|
|
Webcast
Transcript
|
|
|
|
|
Ethical and Social Issues Associated with Using Race and Genetics in the Study of Differential Drug Response |
|
|
|
Wylie Burke, M.D., Ph.D.
Professor and Chair, Department of Medical History and Ethics
University of Washington |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Q&A and Committee Discussion |
|
|
|
Facilitator: Dr. Winn-Deen |
|
|
|
Webcast
Transcript
|
|
|
|
|
Discussion of Next Steps, Work Plan, and Final Work Product for Pharmacogenomics |
|
|
|
Facilitators: Dr. Winn-Deen and Ms. Berry |
|
|
|
Webcast
Transcript
|
|
|
|
|
June 16, 2005 - Current Issues in Pharmacogenomics (all day) |
|
|
|
|
Session Overview and Goals |
|
|
|
Emily Winn-Deen, Ph.D.
Chair, SACGHS Pharmacogenomics Task Force |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Fundamentals of Pharmacogenomics: Origins, Definitions and Concepts |
|
|
|
Richard M. Weinshilboum, M.D.
Professor of Molecular Pharmacology and Experimental Therapeutics
and Medicine
Mayo Clinic College of Medicine |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Q&A and Discussion |
|
|
|
Webcast
Transcript
|
|
|
|
|
Pharmacogenomics: The Public Health Perspective |
|
|
|
Robert L. Davis, M.D., M.P.H.
Professor, Department of Epidemiology
University of Washington School of Public Health |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Q & A and Discussion |
|
|
|
Webcast
Transcript
|
|
|
|
|
Pharmacogenomics in the Practice of Medicine |
|
|
|
Dr. Weinshilboum |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Q&A and Discussion |
|
|
|
Dr. Weinshilboum |
|
|
|
Webcast
Transcript
|
|
|
|
|
Perspectives from Industry |
|
|
|
Webcast
Transcript
|
|
|
|
|
Eric Lai, Ph.D.
Vice President
Discovery and Pipeline Genetics
GlaxoSmithKline |
|
|
|
Slides
|
|
|
|
|
Walter Koch, Ph.D.
Vice President and Head of Research
Roche Molecular Systems |
|
|
|
Slides
|
|
|
|
|
Q&A and Discussion |
|
|
|
Webcast
Transcript
|
|
|
|
|
Public Comments |
|
|
|
Webcast
Transcript
|
|
|
|
|
HHS Efforts and Future Directions in Pharmacogenomics |
|
|
|
|
Rochelle Long, Ph.D.
Chief, Pharmacological & Physiological Sciences Branch
National Institute of General Medical Sciences, NIH |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Felix Frueh, Ph.D.
Associate Director for Genomics
Office of Clinical Pharmacology and Biopharmaceutics
Center for Drug Evaluation and Research, FDA |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Muin Khoury, M.D., Ph.D.
Associate Director for Genomics
Director
Office of Genomics and Disease Prevention, CDC |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Q&A and Discussion |
|
|
|
Webcast
Transcript
|
|
|
|
|
Ethical, Legal and Social Implications of Pharmacogenomics |
|
|
|
Patricia Deverka, M.D., M.S., M.B.E.
Fellow
Center for Genome Ethics, Law & Policy
Institute for Genome Sciences & Policy
Duke University |
|
|
|
Slides
Webcast
Transcript
|
|
|
|
|
Q&A and Discussion |
|
|
|
Webcast
Transcript
|
|
|
|
|
Full Committee Discussion and Next Steps for Pharmacogenomics |
|
|
|
Facilitators: Dr. Willard and Dr. Winn-Deen |
|
|
|
Webcast
Transcript
|
|
|
|
|
October 19, 2004 - Discussion of Proposed Plans for Addressing SACGHS Priority Issues |
|
|
|
|
Pharmacogenomics |
|
|
|
Emily Winn-Deen, Ph.D.
Chair, SACGHS Task Force on Pharmacogenomics |
|
|
|
Webcast
Transcript
|
|
|
Top of Page |